首頁 > 市場調查報告書 > 醫療設備

透析設備

市場調查報告書

商品編碼

1623497

2024 年至 2031 年血液分離市場規模（按產品、流程、技術、應用、最終用戶和地區劃分）

Apheresis Market Size by Product, Procedure, Technology, Application, End-User & Region for 2024-2031

出版日期: 2024年08月10日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血液分離術市場規模及預測 2024-2031

由於血液相關疾病的盛行率不斷上升以及對治療性血液分離手術的需求不斷增加，血液分離市場正在經歷顯著增長。此外，血液採集設備和一次性用品的技術進步正在提高治療效果並促進市場擴大。因此，預計 2024 年市場規模將超過 39.9 億美元，2031 年將達到約 63 億美元。

市場正在全球擴張，其中北美是主要地區。關鍵推動因素包括增加醫療保健投資和提高對治療性血液分離術的認識。隨著患者人數不斷增加以及醫療保健基礎設施不斷改善，亞太地區的新興市場也正在獲得發展動力。在白血球分離術需求不斷增長的推動下，預計 2024 年至 2031 年期間市場複合年增長率為 12.6%。

定義/概述

血液分離術是一種用於分離和去除某些血液成分（例如血漿、血小板和白血球）並將剩餘血液送回給患者的醫療程序。

血液分離術廣泛用於治療自體免疫疾病、血液疾病和心血管疾病。它還支持捐血，包括血漿和血小板採集，改善各種臨床環境中的患者護理。

由於技術進步、醫療保健基礎設施的擴大以及對血液成分治療的需求不斷增加（尤其是在新興市場），預計未來血液分離市場將會成長。

血液相關疾病的增加將如何推動血液白血球分離術市場的成長？

自體免疫疾病、血液系統惡性腫瘤和心血管疾病等血液相關疾病的發生率不斷增加，推動了血液白血病產業的發展。這些疾病經常需要治療特定的血液成分，從而增加了透過血液分離和回收目標血液成分的單採程序的需求。此外，血液分離技術的創新和醫療保健專業人員對這些程序的好處的認識不斷提高，正在推動市場擴張。增加對血液白血球分離技術研究和開發的投資將擴大治療選擇並改善患者的治療效果。此外，老年人口的增加使得他們更容易患血液疾病，這也推動了對有效的血液分離治療的需求，從而促進了市場的成長。整體而言，血液相關疾病的盛行率不斷上升是血液白血球分離術市場發展的主要驅動力。

血液分離手術的高成本如何對血液分離市場的成長構成課題？

血液白血球分離術的高成本是市場擴張的一大阻礙因素。這些治療通常需要專門的設備、專門的人員和大量的醫院資源，從而增加營運成本。因此，許多醫療保健提供者不願投資血液分離技術，從而減少了患者接受治療的機會。此外，高昂的成本會對個人和醫療保健系統造成壓力，特別是在保險覆蓋和財政資源有限的地區。這種高成本障礙可能會阻止患者選擇白血球分離術，從而減少市場需求。此外，來自更廉價的替代療法的競爭可能會阻礙血液白血球分離術市場的成長。總體而言，血液白血球分離手術的高成本對該行業的長期成長構成了重大障礙。

The Apheresis Market is witnessing significant growth due to rising incidences of blood-related disorders and the increasing demand for therapeutic apheresis procedures. Technological advancements in apheresis devices and disposables are also contributing to the market's expansion, enhancing treatment efficacy. This is likely to enable the market size to surpass USD 3.99 Billion valued in 2024 to reach a valuation of around USD 6.3 Billion by 2031.

The market is expanding globally, with North America as the leading region. Key drivers include increasing healthcare investments and rising awareness of therapeutic apheresis. Emerging markets in Asia-Pacific are also gaining traction, driven by growing patient populations and improving healthcare infrastructure. The rising demand for apheresis is enabling the market to grow at aCAGR of 12.6% from 2024 to 2031.

Definition/Overview

Apheresis is a medical procedure used to separate and remove specific blood components, such as plasma, platelets, or white blood cells, while returning the remaining blood to the patient.

Apheresis is widely used in treating autoimmune disorders, hematological diseases and cardiovascular conditions. It also supports blood donations, including plasma and platelet collection, improving patient care in various clinical settings.

The apheresis market is poised for future growth, driven by advancements in technology, expanding healthcare infrastructure and increasing demand for blood component therapies, particularly in emerging markets.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Does the Rising Prevalence of Blood-Related Disorders Help in Driving the Growth Of The Apheresis Market?

The increasing frequency of blood-related ailments, such as autoimmune diseases, hematologic malignancies, and cardiovascular problems, is driving the apheresis industry. As these conditions frequently necessitate particular blood component therapy, the demand for apheresis procedures, which separate and collect targeted blood components, grows. Furthermore, innovations in apheresis technology and increasing awareness among healthcare professionals about the benefits of these procedures help to drive market expansion. Increasing investment in apheresis research and development expands treatment options and improves patient outcomes. Furthermore, the growing geriatric population, which is more sensitive to blood problems, increases the demand for effective apheresis treatments, driving market growth. Overall, the increasing prevalence of blood-related illnesses is a significant driver of the apheresis market.

How Is the High Cost of Apheresis Procedures Challenging the Growth Of The Apheresis Market?

The high cost of apheresis operations significantly limits the market's expansion. These treatments frequently necessitate specialized equipment, expert personnel, and substantial hospital resources, resulting in increasing operating expenses. As a result, many healthcare providers may hesitant to invest in apheresis technology, reducing patient access to these treatments. Furthermore, the high costs can put a strain on individuals and healthcare systems, particularly in areas with limited insurance coverage or financial resources. This expensive barrier may prevent patients from choosing for apheresis, reducing market demand. Furthermore, competition from less expensive alternative treatments may impede the apheresis market's growth. Overall, the high prices of apheresis operations represent a significant barrier to long-term industry growth.

Category-wise Acumens

How Will the Increasing Adoption of Automated Technologies Drive the Growth of The Apheresis Devices Segment?

The increasing adoption of automated technologies in apheresis devices is driving the growth of the segment by enhancing procedure accuracy, reducing manual errors and improving patient outcomes. These advanced devices offer greater efficiency in blood component separation, leading to their widespread use in both therapeutic and donation settings. As healthcare providers prioritize automation for better results and time savings, the demand for apheresis devices continues to grow, boosting the market segment's expansion.

How Will the Rising Use of Apheresis in Treating Autoimmune Disorders Drive the Growth of The Application Segment?

The rising use of apheresis in treating autoimmune disorders is driving growth in the Application segment by providing effective, targeted therapies for conditions like multiple sclerosis and Guillain-Barre syndrome. Apheresis helps remove harmful antibodies or immune complexes, offering significant clinical benefits. As the prevalence of autoimmune diseases increases, the demand for apheresis treatments expands, leading to the growth of this segment in both therapeutic and healthcare applications.

Country/Region-wise Acumens

Will The Advanced Healthcare Infrastructure Drive the Dominance of North America in The Apheresis Market?

North America's advanced healthcare infrastructure contributes significantly to the region's supremacy in the apheresis market. The well-established healthcare infrastructure make it easier to integrate innovative technologies, resulting in more efficient apheresis processes. Significant investments in cutting-edge medical technology improve the efficacy and accessibility of these therapies. Furthermore, growing awareness of the therapeutic benefits of apheresis, particularly for autoimmune diseases and hematologic disorders, is broadening the patient base. The region also benefits from a strong research climate, which promotes advances in apheresis technology. Additionally, regulatory backing and increasing healthcare expenditure help to drive market expansion. These factors combine to establish North America as a market leader in apheresis, fueling its sustained growth.

Will The Growing Healthcare Investments and Expanding Patient Population Drive the Rapid Growth of Asia-Pacific in The Apheresis Market?

The growing healthcare investments and expanding patient population are key drivers of Asia-Pacific's rapid growth in the Apheresis Market. As countries like China and India enhance their healthcare infrastructure, demand for advanced therapeutic procedures increases. Additionally, the rising prevalence of blood-related disorders and increasing awareness of apheresis treatments fuel market expansion. This combination of factors is positioning Asia-Pacific as the fastest-growing region in the global apheresis market.

Competitive Landscape

The apheresis market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Apheresis market include:

Asahi Kasei Corporation

Braun Melsungen AG

Cerus Corporation

Fresenius Kabi

Haemonetics Corporation

Charles River Laboratories International, Inc.

Kaneka Corporation

Kawasumi Laboratories Inc.

Nikkiso Co. Ltd

Terumo BCT

Latest Developments

In September 2024, Fresenius Kabi announced the divestment of its IV manufacturing site in Chile to Medifarma, streamlining its production network as part of its Vision 2026 strategy.

In June 2024, Asahi Kasei Corporation introduced a new membrane system for the production of sterile water used in injections, enhancing its product offerings in the healthcare sector.

In August 2023, Terumo BCT, Inc. launched a training program initiative aimed at supporting cell and gene therapy manufacturers, which is expected to improve cell collection processes and boost therapeutic commercialization.

In March 2024, Haemonetics Corporation received FDA approval for its new apheresis device designed to enhance the efficiency of blood component collection, marking a significant advancement in their product line.